177 related articles for article (PubMed ID: 27615536)
1. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
2. Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
Kaneda T; Kurata T; Yoshida T; Kibata K; Yoshioka H; Yanagimoto H; Takeda K; Yoshida T; Tsuta K
BMC Cancer; 2022 Feb; 22(1):154. PubMed ID: 35135489
[TBL] [Abstract][Full Text] [Related]
3. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
Kashima J; Okuma Y; Shimizuguchi R; Chiba K
Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
[TBL] [Abstract][Full Text] [Related]
4. Re-inventing a better wheel? Serplulimab for squamous cell lung cancer.
Huang DD; Yang JC
Cancer Cell; 2024 Feb; 42(2):172-174. PubMed ID: 38350419
[TBL] [Abstract][Full Text] [Related]
5. Stopping immunotherapy after 2 years is practical in patients with advanced non-small cell lung cancer.
Nierengarten MB
Cancer; 2023 Oct; 129(19):2925-2926. PubMed ID: 37656153
[No Abstract] [Full Text] [Related]
6. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
[TBL] [Abstract][Full Text] [Related]
7. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Gastroesophageal Cancer.
Goode EF; Smyth EC
J Clin Med; 2016 Sep; 5(10):. PubMed ID: 27669318
[TBL] [Abstract][Full Text] [Related]
11. A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab.
Basnet A; Saad N; Benjamin S
Anticancer Res; 2016 Sep; 36(9):4795-8. PubMed ID: 27630330
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
[TBL] [Abstract][Full Text] [Related]
14. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C; Dingemans AC; Gray JE; Nakagawa K; Nicolson M; Peters S; Reck M; Wu YL; Brustugun OT; Crinò L; Felip E; Fennell D; Garrido P; Huber RM; Marabelle A; Moniuszko M; Mornex F; Novello S; Papotti M; Pérol M; Smit EF; Syrigos K; van Meerbeeck JP; van Zandwijk N; Yang JC; Zhou C; Vokes E
J Thorac Oncol; 2017 Feb; 12(2):194-207. PubMed ID: 27729297
[TBL] [Abstract][Full Text] [Related]
15. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Tang C; Welsh JW; de Groot P; Massarelli E; Chang JY; Hess KR; Basu S; Curran MA; Cabanillas ME; Subbiah V; Fu S; Tsimberidou AM; Karp D; Gomez DR; Diab A; Komaki R; Heymach JV; Sharma P; Naing A; Hong DS
Clin Cancer Res; 2017 Mar; 23(6):1388-1396. PubMed ID: 27649551
[No Abstract] [Full Text] [Related]
18. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Cogswell J; Inzunza HD; Wu Q; Feder JN; Mintier G; Novotny J; Cardona DM
Mol Diagn Ther; 2017 Feb; 21(1):85-93. PubMed ID: 27667773
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Ford J; Thuro BA; Thakar S; Hwu WJ; Richani K; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(4):e82-e85. PubMed ID: 27662198
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab plus nivolumab for advanced melanoma.
Hassel JC
Lancet Oncol; 2016 Nov; 17(11):1471-1472. PubMed ID: 27617662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
